Circulating pegfr is a candidate response biomarker of cetuximab therapy in colorectal cancer

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6346-6356

  Katsila, Theodora ^a   Juliachs, Mercèe ^a   Gregori, Josep ^a,b   Macarulla, Teresa ^c   Villarreal, Laura ^a   Bardelli, Alberto ^d,e   Torrance, Chris ^f   Elez, Elena ^c   Tabernero, Josep ^a,c   Villanueva, Josep ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF TURIN   (Italy)

^e FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^f Molecular Biotechnology Center   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEOME; RAS PROTEIN; TUMOR MARKER;

APOPTOSIS; ARTICLE; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; LOADING DRUG DOSE; NONHUMAN; ONCOGENE K RAS; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REPEATED DRUG DOSE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; CANCER STAGING; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; GENETICS; METABOLISM; METASTASIS; MULTICELLULAR SPHEROID; MUTATION; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; PROTEOMICS; TREATMENT OUTCOME; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; PROTEOME; PROTEOMICS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84919622759     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0361     Document Type: Article

References (34)

1. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-36.
2. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
3. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
4. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008;26:4000
5. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-15.
6. Di Fiore F, Charbonnier F, Lefebure B, Laurent M, Le Pessot F, Michel P, Frebourg T Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. Br J Cancer 2008;99:551-52.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
8. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-37.
9. Lìevre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-79.
10. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008;19:734-38.
11. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-96.
12. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812-20.
13. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with firstline chemotherapy with or without cetuximab. J Clin Oncol 2012;30:3570-77.
14. Rifai N, Gillette MA, Carr S. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83.
15. Lawlor K, Nazarian A, Lacomis L, Tempst P, Villanueva J. Pathwaybased biomarker search by high-throughput proteomics profiling of secretomes. Proteome Res 2009;8:1489-03.
16. Villarreal L, Méendez O, Salvans C, Gregori J, Baselga J, Villanueva J. Unconventional secretion is a major contributor of cancer cell line secretomes. Mol Cell Proteomics 2013;12:1046-60.
17. Mathias RA, Wang B, Ji H, Kapp EA, Moritz RL, Zhu HJ, Simpson RJ. Secretome-based proteomic profiling of Ras-transformedMDCK cells reveals extracellular modulators of epithelial-mesenchymal transition. J Proteome Res 2009;8:2827-37.
18. Fijneman RJ, de Wit M, Pourghiasian M, Piersma SR, Pham TV, Warmoes MO, et al. Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer. Clin Cancer Res 2012;18:2613-24.
19. Grønborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 2006;5:157-71.
20. Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, et al. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A 2008;105:20864-69.
21. Gregori J, Villarreal L, Sáanchez A, Baselga J, Villanueva J. An effect size filter improves the reproducibility in spectral counting-based comparative proteomics. J Proteomics 2013;95:55-65.
22. Derer S, Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S, et al. Oncogenic KRAS impairs EGFR antibodies' efficiency by C/ EBPb-dependent suppression of EGFR expression. Neoplasia 2012;14:190-205.
23. Nickel W, Rabouille C. Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol 2009;10:148-55.
24. Luca AC, Mersch S, Deenen R, Schmidt S, Messner I, Sch €afer KL, et al. Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PLoS ONE 2013;8: e59689
25. Fang DD, Kim YJ, Lee CN, Aggarwal S, McKinnon K, Mesmer D, et al. Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer 2010;102:1265-75.
26. Zou J, Yu XF, Bao ZJ, Dong J. Proteome of human colon cancer stem cells: a comparative analysis. World J Gastroenterol 2011;17:1276-85.
27. Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010;28:1181-89.
28. Barderas R, Mendes M, Torres S, Bartolomée RA, Lóopez-Lucendo M, Villar-Váazquez R, et al. In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion. Mol Cell Proteomics 2013;12:1602-20.
29. Baker BM, Chen CS. Deconstructing the third dimension-how 3D culture microenvironments alter cellular cues. J Cell Science 2012;125:3015-24.
30. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughartc LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010;148:3-15.
31. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 2012;227:658-67.
32. Skog J, W Urdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10:1470-76.
33. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008;10:619-24.
34. Personeni N, Hendlisz A, Gallez J, Galdon M, Larsimont D, Vanlaethem J, et al. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. Semin Oncol 2005;32:59-62.